---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-005236"
form_type: "8-K"
ticker: "TVGN"
cik: "0001860871"
company_name: "Tevogen Bio Holdings Inc."
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T12:19:48.879386+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tevogen Bio inks related-party facility deal with CD8 for cell therapy production

## Summary
- Agreement with CD8 Technology Services (associated with >5% holder Dr. Manmohan Patel) for turn-key GMP cell therapy production facility.
- Tevogen to provide primary staff and operations; facility supports both pre-clinical research and GMP production.
- Initial term of 12 months, auto-renewing; specific costs, scope, and timelines to be set in future work orders.
- Agreement formalizes previously announced letter of intent and aligns with previously stated topline forecasts.

## SEC filing metadata
- accession: 0001641172-25-005236
- form_type: 8-K
- ticker: TVGN
- cik: 0001860871
- company_name: Tevogen Bio Holdings Inc.
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860871/000164117225005236/0001641172-25-005236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860871/000164117225005236/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-005236
- JSON: https://secwatch.observer/filing/0001641172-25-005236.json
- Plain text: https://secwatch.observer/filing/0001641172-25-005236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.